Literature DB >> 17211019

The value of antihypertensive drugs: a perspective on medical innovation.

David M Cutler1, Genia Long, Ernst R Berndt, Jimmy Royer, Andrée-Anne Fournier, Alicia Sasser, Pierre Cremieux.   

Abstract

Using national survey data and risk equations from the Framingham Heart Study, we quantify the impact of antihypertensive therapy changes on blood pressures and the number and cost of heart attacks, strokes, and deaths. Antihypertensive therapy has had a major impact on health. Without it, 1999-2000 average blood pressures (at age 40+) would have been 10-13 percent higher, and 86,000 excess premature deaths from cardiovascular disease would have occurred in 2001. Treatment has generated a benefit-to-cost ratio of at least 6:1, but much more can be achieved. More effective use of antihypertensive medication would have an impact on mortality akin to eliminating all deaths from medical errors or accidents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211019     DOI: 10.1377/hlthaff.26.1.97

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  21 in total

1.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

2.  Spending more money, saving more lives? The relationship between avoidable mortality and healthcare spending in 14 countries.

Authors:  Richard Heijink; Xander Koolman; Gert P Westert
Journal:  Eur J Health Econ       Date:  2012-06-08

3.  Cost-effectiveness of hypertension therapy according to 2014 guidelines.

Authors:  Andrew E Moran; Michelle C Odden; Anusorn Thanataveerat; Keane Y Tzong; Petra W Rasmussen; David Guzman; Lawrence Williams; Kirsten Bibbins-Domingo; Pamela G Coxson; Lee Goldman
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

4.  Coronary heart disease and stroke attributable to major risk factors is similar in Argentina and the United States: the Coronary Heart Disease Policy Model.

Authors:  Andrew Moran; Vincent Degennaro; Daniel Ferrante; Pamela G Coxson; Walter Palmas; Raul Mejia; Eliseo J Perez-Stable; Lee Goldman
Journal:  Int J Cardiol       Date:  2011-05-07       Impact factor: 4.164

5.  Access to medications for medicare enrollees related to race/ethnicity: Results from the 2013 Medicare Current Beneficiary Survey.

Authors:  Deborah A Taira; Chengli Shen; Marshaleen King; Doug Landsittel; Mary Helen Mays; Tetine Sentell; Janet Southerland
Journal:  Res Social Adm Pharm       Date:  2016-11-23

6.  Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.

Authors:  Nathalie Moise; Chen Huang; Anthony Rodgers; Ciaran N Kohli-Lynch; Keane Y Tzong; Pamela G Coxson; Kirsten Bibbins-Domingo; Lee Goldman; Andrew E Moran
Journal:  Hypertension       Date:  2016-05-15       Impact factor: 10.190

Review 7.  Changes in Hypertension Prevalence, Awareness, Treatment, and Control in High-, Middle-, and Low-Income Countries: An Update.

Authors:  Renata Cifkova; George Fodor; Peter Wohlfahrt
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

8.  Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD.

Authors:  Rodrigo Refoios Camejo; Rodrigo Refoios Camejo; Clare McGrath; Marisa Miraldo; Frans Rutten
Journal:  Eur J Health Econ       Date:  2013-05-03

Review 9.  Risk factor management to prevent first stroke.

Authors:  Tatjana Rundek; Ralph L Sacco
Journal:  Neurol Clin       Date:  2008-11       Impact factor: 3.806

10.  Hypertension assessment and management: role for digital medicine.

Authors:  Peter Godbehere; Phillip Wareing
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-02-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.